This week in biotech highlights significant advancements in multiomics, human cell research, and innovative production methods involving microbes.
Novogene Europe has bolstered its multiomics capabilities with the launch of an Untargeted Metabolomics Service at its Cambridge Omics Centre. This service aims to enhance the understanding of molecular interactions by integrating metabolomic data with genomics and other life sciences, providing researchers with deeper insights into biological functions.
In a bid to make human cell-based research more accessible, bit.bio has introduced two new cell culture media kits tailored for its human iPSC-derived neurons and microglia. These kits are designed to simplify the research process, lowering barriers for laboratories interested in human cell applications.
Meanwhile, Metabolon is expanding its Microbiome Panel, which now screens over 800 metabolites linked to microbial activity. This development is particularly relevant for researchers in multiomics, offering a comprehensive view of microbiome interactions and their implications for health and disease.
Lastly, a partnership worth $5 million between the Alzheimer’s Drug Discovery Foundation and The Michael J. Fox Foundation aims to expedite the development of minimally invasive biomarkers for Alzheimer’s and Parkinson’s diseases. This initiative underscores the growing importance of biomarker research in neurodegenerative conditions.
These advancements illustrate the ongoing trend of integrating technology and biological research, paving the way for more effective diagnostic and therapeutic strategies in the life sciences sector.